Insider filing
Traded Oct 20 · filed the same day
Routine share withholding; mechanical by default.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Sep 24, 2026 · Filed Sep 29, 2026
The CEO of Monopar Therapeutics sold $911K of Monopar Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$910,718
Shares × reported transaction price
43 days after results of Aug 12, 2026, 49 days before results of Nov 12, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $88.84 on Sep 24, 2026, 77% above its 52-week low and 28% below its high, after a 23% drop over the previous 30 trading days
52-week range $50.12 (Apr 29, 2026) to $123.84 (Aug 19, 2026), 53% of the way up, from 251 adjusted closes. 30 trading days earlier: $114.90 on Aug 12, 2026. Describes the past only, not a forecast
RSI 27, 16% above its 200-day average, 20% under its 50-day average, 28% below the 52-week high, 20-day volatility 44% a year, against the S&P 500: −20 points over 1 month, −3 points over 3 months, +39 points over 6 months
From the adjusted closes up to Sep 24, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +5.2% | +1.9% | +3.3% |
| 30 days | −11.7% | −0.9% | −10.8% |
Past results only. Not a forecast.
Insider filing
Traded Oct 20 · filed the same day
Routine share withholding; mechanical by default.
Insider filing
Traded Oct 1 · filed 5 days later
Derivative exercise or conversion — not an open-market buy.
Christopher M Starr (Director) sold ~$362K of Monopar Therapeutics
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.